Attendees who purchased access to the 2016 Annual Meeting webcast were sent login information on May 11, 2016.

Login for full access:

Username and password are not your MyAACR account information

Search:

Search for text in:

separate each search
term with a space

Multiple terms:

Additional Search Filters:

Conference Years:

Days Within Meeting:

Conferences:

Availability:

Participation Type:

Presentations Access:

Presentation Access:

Topic Tracks*:

Organ Site Tracks*:

  • Sort by:
  • Browse by:
<< first | < prev page: of 25 records per page: next > | last >>
pages: 1 2 3 4 5 6 ... 22 23 24 25 presentations: 1 to 25 of 606
Transformative Clinical Trials in Breast Cancer
Primary analysis of the EORTC 10041/ BIG 3-04 MINDACT study: a prospective, randomized study evaluating the clinical utility of the 70-gene signature (MammaPrint) combined with common clinical-pathological criteria for selection of patients for adjuvant chemotherapy in breast cancer with 0 to 3 positive nodes
Martine Piccart
Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium
from AACR Annual Meeting 2016 on April 18, 2016 10:30 AM-12:30 PM
Transformative Clinical Trials in Breast Cancer
Discussant
Harold J Burstein
Dana-Farber Cancer Institute, Boston, MA, United States
from AACR Annual Meeting 2016 on April 18, 2016 10:30 AM-12:30 PM
Transformative Clinical Trials in Breast Cancer
Anti-proliferative response and predictive biomarkers to palbociclib in early breast cancer: The Preoperative Palbociclib (POP) randomized trial
Monica Arnedos
Institut Gustave Roussy, Villejuif, France
from AACR Annual Meeting 2016 on April 18, 2016 10:30 AM-12:30 PM
Transformative Clinical Trials in Breast Cancer
Discussant
Nancy E. Davidson
University of Pittsburgh Cancer Institute, Pittsburgh, PA, United States
from AACR Annual Meeting 2016 on April 18, 2016 10:30 AM-12:30 PM
Transformative Clinical Trials in Breast Cancer
Efficacy of T-DM1+pertuzumab over standard therapy for HER2+ breast cancer: Results from the neoadjuvant I-SPY 2 TRIAL
Angela M DeMichele
University of Pennsylvania, Philadelphia, PA, United States
from AACR Annual Meeting 2016 on April 18, 2016 10:30 AM-12:30 PM
Transformative Clinical Trials in Breast Cancer
Discussant
Mark D Pegram
UCLA School of Medicine, Los Angeles, CA, United States
from AACR Annual Meeting 2016 on April 18, 2016 10:30 AM-12:30 PM
Transformative Clinical Trials in Breast Cancer
Low-fat dietary pattern and breast cancer mortality in the Women's Health Initiative (WHI) randomized trial
Rowan T Chlebowski
Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Torrance, CA, United States
from AACR Annual Meeting 2016 on April 18, 2016 10:30 AM-12:30 PM
Tumor Immunology and Immunotherapy for Non-Immunologists: How Tumors Regulate Immune Responses
Inhibiting immune checkpoints
Mary L. Disis
University of Washington, Seattle, WA, United States
from AACR Annual Meeting 2016 on April 16, 2016 8:00 AM-10:00 AM
Tumor Immunology and Immunotherapy for Non-Immunologists: How Tumors Regulate Immune Responses
Regulatory T cells
Dario A. Vignali
Univ. of Pittsburgh School of Medicine, Pittsburgh, PA, United States
from AACR Annual Meeting 2016 on April 16, 2016 8:00 AM-10:00 AM
Tumor Immunology and Immunotherapy for Non-Immunologists: How Tumors Regulate Immune Responses
Regulatory myeloid cells
Dmitry I. Gabrilovich
The Wistar Institute, Philadelphia, PA, United States
from AACR Annual Meeting 2016 on April 16, 2016 8:00 AM-10:00 AM
Tumor Immunology and Immunotherapy for Non-Immunologists: How Tumors Regulate Immune Responses
Galectins and immune response in cancer
Gabriel A. Rabinovich
Instituto de BiologĂ­a y Medicina Experimental, CONICET, Ciudad de Buenos Aires, Argentina
from AACR Annual Meeting 2016 on April 16, 2016 8:00 AM-10:00 AM
Breast Cancer Targets in 2016
Introduction
Lisa A. Carey
UNC Lineberger Comp. Cancer Center, Chapel Hill, NC, United States
from AACR Annual Meeting 2016 on April 16, 2016 10:15 AM-12:15 PM
Breast Cancer Targets in 2016
Targeted therapy for ESR1 positive breast cancer
Matthew J. Ellis
Baylor College of Medicine Cancer Ctr., Houston, TX, United States
from AACR Annual Meeting 2016 on April 16, 2016 10:15 AM-12:15 PM
Breast Cancer Targets in 2016
Targeting HER2/3 in breast cancer: An overview of genomic changes, drug development and clinical trials
Ron Bose
Washington Univ. School of Medicine, Saint Louis, MO, United States
from AACR Annual Meeting 2016 on April 16, 2016 10:15 AM-12:15 PM
Breast Cancer Targets in 2016
Targeting DNA repair
James M. Ford
Stanford University, Stanford, CA, United States
from AACR Annual Meeting 2016 on April 16, 2016 10:15 AM-12:15 PM
Breast Cancer Targets in 2016
Resistance to P13K inhibitors: A problem or an opportunity?
Maurizio Scaltriti
Memorial Sloan Kettering Cancer Center, New York, NY, United States
from AACR Annual Meeting 2016 on April 16, 2016 10:15 AM-12:15 PM
Clinical Trials Design Methods Workshop, Part 2: Breakthroughs and Challenges of Combination Immunotherapy Trials
Chairperson
Elizabeth M. Jaffee
Johns Hopkins University, Baltimore, MD, United States
from AACR Annual Meeting 2016 on April 16, 2016 10:15 AM-12:15 PM
Clinical Trials Design Methods Workshop, Part 2: Breakthroughs and Challenges of Combination Immunotherapy Trials
Successes and challenges in designing combination immunotherapy clinical trials for breast cancer
Leisha A Emens
Johns Hopkins Univ. School of Medicine, Baltimore, MD, United States
from AACR Annual Meeting 2016 on April 16, 2016 10:15 AM-12:15 PM
Clinical Trials Design Methods Workshop, Part 2: Breakthroughs and Challenges of Combination Immunotherapy Trials
Issues faced by industry in developing safe and effective combination immunotherapies
Ira Mellman
Genentech, Inc., South San Francisco, CA, United States
from AACR Annual Meeting 2016 on April 16, 2016 10:15 AM-12:15 PM
Clinical Trials Design Methods Workshop, Part 2: Breakthroughs and Challenges of Combination Immunotherapy Trials
Statistical challenges in designing combination immunotherapy clinical trials
Katy Simonsen
Bristol-Myers Squibb Co., Princeton, NJ, United States
from AACR Annual Meeting 2016 on April 16, 2016 10:15 AM-12:15 PM
Clinical Trials Design Methods Workshop, Part 2: Breakthroughs and Challenges of Combination Immunotherapy Trials
FDA's point of view on trial designs for accelerating combination immunotherapies across multiple tumor types
Tatiana Prowell
U.S. Food and Drug Administration, Silver Spring, MD, United States
from AACR Annual Meeting 2016 on April 16, 2016 10:15 AM-12:15 PM
Alterations and Inhibition of the Spliceosome
Basic mechanisms of splicing catalysis and regulation
Clara L Kielkopf
University of Rochester Medical Center, Rochester, NY, United States
from AACR Annual Meeting 2016 on April 16, 2016 1:00 PM-3:00 PM
Alterations and Inhibition of the Spliceosome
Genetics and biological studies of spliceosomal mutations in cancer
Matthew Walter
Washington University, Saint Louis, MO, United States
from AACR Annual Meeting 2016 on April 16, 2016 1:00 PM-3:00 PM
Alterations and Inhibition of the Spliceosome
Understanding and targeting SF3B1 in cancer
Silvia Buonamici
H3 Biomedicine, Boston, MA, United States
from AACR Annual Meeting 2016 on April 16, 2016 1:00 PM-3:00 PM
Alterations and Inhibition of the Spliceosome
The role of splicing regulatory proteins in cancer
Omar I Abdel-Wahab
Mem. Sloan-Kettering Cancer Ctr., New York, NY, United States
from AACR Annual Meeting 2016 on April 16, 2016 1:00 PM-3:00 PM
<< first | < prev page: of 25 records per page: next > | last >>
pages: 1 2 3 4 5 6 ... 22 23 24 25 presentations: 1 to 25 of 606